Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 plus pembrolizumab neoadjuvant phase II trial in triple-negative breast cancer
ChiCTR2500103244Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Pathological complete response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500103244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103244.